Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Delayed Nasdaq  -  04:00 2022-10-06 pm EDT
731.86 USD   -1.85%
07:42aRBC Raises Price Target on Regeneron Pharmaceuticals to $702 From $686, Maintains Sector Perform Rating
MT
10/05Insider Sell: Regeneron Pharmaceuticals
MT
10/05Insider Sell: Regeneron Pharmaceuticals
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wall Street rises on tech, earnings boost as recession fears ease

08/03/2022 | 01:07pm EDT

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window.)

* U.S. service sector unexpectedly picks up in July

* PayPal rises after bumping annual profit outlook

* Apple gains 3.5%, Microsoft adds 2.7%

* Moderna jumps on $3 billion share buyback plan

* Indexes: Dow 1.08%, S&P 1.30%, Nasdaq 2.13%

Aug 3 (Reuters) - Wall Street's major indexes surged on Wednesday, with gains in big technology companies lifting the Nasdaq to near three-month highs as key readings on the services sector and new orders helped calm recession fears.

A fresh batch of strong results from PayPal and CVS Health Corp also boosted sentiment in a largely upbeat second quarter that has helped markets bounce back from the fallout of the Ukraine war, rising inflation and a rise in borrowing costs.

Apple Inc rose 3.5% and Microsoft Corp added 2.7%, helping the broader growth stocks index outperform its value counterpart.

"An economy that is not falling into recession but is not roaring higher at this time would have you shift away from value stocks into growth," Kim Forrest, chief investment officer at Bokeh Capital Management said.

PayPal Holdings jumped 9.5% as the fintech firm raised its annual profit guidance and said activist investor Elliott Management has an over $2 billion stake.

CVS Health Corp gained 5.4% as the largest U.S. pharmacy chain raised its annual profit forecast after posting strong quarterly results.

The benchmark S&P 500 index and tech-heavy Nasdaq are up 13.3% and 18.2%, respectively, from the lows hit in mid-June, but are still in a bear market.

Wall Street started August on a sour note as factory activity in the United States, China and Eurozone weakened in July. But worries eased on Wednesday as the U.S. services sector, which accounts for more than two-third of the economic activity, rebounded unexpectedly.

It rose in July to 56.7 from 55.3 in June amid strong order growth, while supply bottlenecks and price pressures eased. A separate survey showed new orders for U.S.-manufactured goods increased solidly in June.

"(Today's) data further support our view that service-sector activity will hold up well in the near-term," Wells Fargo economists wrote in a note.

"The recent easing in prices may in part be due to lower in commodity prices, but nonetheless this broad easing of price pressure will be welcome news for policymakers tasked with quelling inflation."

Meanwhile, Richmond Federal Reserve President Thomas Barkin on Wednesday joined policymakers voicing determination that the U.S. central bank is committed to getting inflation under control and returning it to 2% target.

At 12:27 p.m. ET, the Dow Jones Industrial Average was up 351.02 points, or 1.08%, at 32,747.19, the S&P 500 was up 53.19 points, or 1.30%, at 4,144.38, and the Nasdaq Composite was up 263.40 points, or 2.13%, at 12,612.16.

Moderna Inc surged 15.1% after the vaccine maker announced a $3 billion share buyback plan.

Regeneron Pharmaceuticals climbed 7.6% after it beat quarterly revenue estimates, while coffee chain Starbucks Corp rose 3.4% on upbeat quarterly profit.

Advancing issues outnumbered decliners by a 1.85-to-1 ratio on the NYSE and by a 2.29-to-1 ratio on the Nasdaq.

The S&P index recorded two new 52-week highs and 30 new lows, while the Nasdaq recorded 40 new highs and 27 new lows. (Reporting by Aniruddha Ghosh and Devik Jain in Bengaluru; Editing by Sriraj Kalluvila and Arun Koyyur)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
APPLE INC. -0.66% 145.43 Delayed Quote.-17.72%
MICROSOFT CORPORATION -0.97% 246.79 Delayed Quote.-26.00%
MODERNA, INC. -0.37% 125.15 Delayed Quote.-50.54%
PAYPAL HOLDINGS, INC. 0.63% 94.42 Delayed Quote.-50.24%
REGENERON PHARMACEUTICALS, INC. -1.85% 731.86 Delayed Quote.18.08%
STARBUCKS CORPORATION -0.85% 89.35 Delayed Quote.-24.33%
All news about REGENERON PHARMACEUTICALS, INC.
07:42aRBC Raises Price Target on Regeneron Pharmaceuticals to $702 From $686, Maintains Secto..
MT
10/05Insider Sell: Regeneron Pharmaceuticals
MT
10/05Insider Sell: Regeneron Pharmaceuticals
MT
10/04Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Confere..
PR
10/03Regeneron Pharmaceuticals : Management Change/Compensation - Form 8-K
PU
10/03US Stocks Rally After ISM Manufacturing Data; Crude Oil Jumps
MT
10/03US Stocks Start New Quarter Higher as Government Bond Yields, Manufacturing Gauge Drop
MT
10/03Insider Sell: Regeneron Pharmaceuticals
MT
10/03US Stocks Advance Midday After ISM Manufacturing Data; Crude Oil Advances
MT
10/03Goldman Sachs Raises Regeneron Pharmaceuticals Price Target to $970 From $796, Maintain..
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 824 M - -
Net income 2022 3 870 M - -
Net cash 2022 5 450 M - -
P/E ratio 2022 21,4x
Yield 2022 -
Capitalization 79 719 M 79 719 M -
EV / Sales 2022 6,28x
EV / Sales 2023 5,58x
Nbr of Employees 10 715
Free-Float 80,6%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 745,68 $
Average target price 759,36 $
Spread / Average Target 1,84%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.18.08%79 719
VERTEX PHARMACEUTICALS37.53%77 456
BIONTECH SE-46.78%33 340
WUXI APPTEC CO., LTD.-39.54%29 208
GENMAB A/S1.14%22 982
ARGENX SE20.14%20 563